This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Homma, K. Articles by Ogata, T. Search for Related Content PubMed PubMed Citation Articles by Homma, K. Articles by Ogata, T. Related Collections Adrenal and Hypertension Pediatric Endocrinology Female Endocrinology Male Endocrinology

Urine Steroid Hormone Profile Analysis in Cytochrome P450 Oxidoreductase Deficiency: Implication for the Backdoor Pathway to Dihydrotestosterone

Departments of Laboratory Medicine (K.H.) and Pediatrics (T.H.), Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Pediatrics, Dokkyo University School of Medicine Koshigaya Hospital (T.N.), Koshigaya 343-8555, Japan; Division of Endocrinology and Metabolism, Kanagawa Children’s Medical Center (M.A.), Yokohama 232-8555, Japan; Division of Endocrinology and Metabolism, National Center for Child Health and Development (R.H.), Tokyo 157-8535, Japan; Department of Pediatrics, Tohoku University School of Medicine (I.F.), Sendai 980-0878, Japan; Department of Pediatrics, Hokkaido University School of Medicine (T.T.) Sapporo 060-8638, Japan; Department of Pediatrics, Shirakawa Kousei General Hospital (R.T.), Shirakawa 961-0907, Japan; and Department of Endocrinology and Metabolism, National Research Institute for Child Health and Development (M.F., T.O.), Tokyo 157-8535, Japan

Address all correspondence and requests for reprints to: Dr. T. Ogata, Department of Endocrinology and Metabolism, National Research Institute for Child Health and Development, 2-10-1 Ohkura, Setagaya, Tokyo 157-8535, Japan. E-mail: tomogata{at}nch.go.jp.

Context: Although the "backdoor" pathway to dihydrotestosterone has been postulated in the fetal-to-early-infantile period of patients with cytochrome P450 oxidoreductase deficiency (PORD), clinical data in support of this pathway remain limited.

Objective: The objective of this study was to obtain clinical evidence for the presence of the backdoor pathway in PORD.

Setting: This was a collaboration study between laboratories and hospitals.

Subjects: Twenty-two Japanese patients with molecularly confirmed PORD and 1763 control subjects participated in this study.

Intervention: Urine steroid profile analysis was performed by gas chromatography/mass spectrometry. In five patients and 776 control subjects, urine samples were obtained before 12 months of age.

Main Outcome Measure: The main outcome measure was identification of a urine steroid(s) indicating the backdoor pathway.

Results: In the PORD patients, pregnanediol, pregnanetriolone, and pregnanetriol were obviously elevated, and the urine steroid ratios reflecting CYP17A1 and CYP21A2 activities were decreased throughout the examined ages. Furthermore, etiocholanolone and 11-hydroxyandrosterone, which should originate almost exclusively from androstenedione in the conventional "frontdoor" pathway, were grossly normal or somewhat decreased since early infancy, whereas androsterone, which can be derived not only from androstenedione and dihydrotestosterone in the conventional frontdoor pathway but also from 5-pregnane-3,17-diol-20-one in the backdoor pathway, was increased during early infancy and remained grossly normal thereafter. Thus, the androsterone to etiocholanolone ratio was increased during early infancy and remained grossly normal thereafter. 5-Pregnane-3,17-diol-20-one was elevated throughout the examined ages.

Conclusions: The increased androsterone excretion during early infancy, as compared with the etiocholanolone and 11-hydroxyandrosterone excretions in the same period, suggests the presence of the backdoor pathway in PORD.

This article has been cited by other articles:

				A. Aguilar, S. Wu, and F. De Luca P450 Oxidoreductase Expressed in Rat Chondrocytes Modulates Chondrogenesis via Cholesterol- and Indian Hedgehog-Dependent Mechanisms Endocrinology, June 1, 2009; 150(6): 2732 - 2739. [Abstract] [Full Text] [PDF]

				M. Fukami, G. Nishimura, K. Homma, T. Nagai, K. Hanaki, A. Uematsu, T. Ishii, C. Numakura, H. Sawada, M. Nakacho, et al. Cytochrome P450 Oxidoreductase Deficiency: Identification and Characterization of Biallelic Mutations and Genotype-Phenotype Correlations in 35 Japanese Patients J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1723 - 1731. [Abstract] [Full Text] [PDF]

				A. V. Pandey, P. Kempna, G. Hofer, P. E. Mullis, and C. E. Fluck Modulation of Human CYP19A1 Activity by Mutant NADPH P450 Oxidoreductase Mol. Endocrinol., October 1, 2007; 21(10): 2579 - 2595. [Abstract] [Full Text] [PDF]

				R. R. Scott, L. G. Gomes, N. Huang, G. Van Vliet, and W. L. Miller Apparent Manifesting Heterozygosity in P450 Oxidoreductase Deficiency and Its Effect on Coexisting 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2318 - 2322. [Abstract] [Full Text] [PDF]

				C. C. Marohnic, S. P. Panda, P. Martasek, and B. S. Masters Diminished FAD Binding in the Y459H and V492E Antley-Bixler Syndrome Mutants of Human Cytochrome P450 Reductase J. Biol. Chem., November 24, 2006; 281(47): 35975 - 35982. [Abstract] [Full Text] [PDF]